Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02833701 · ClinicalTrials.gov registry record · Phase 1
Bevacizumab and Ascorbic Acid in Patients Treating With Recurrent High Grade Glioma
A Phase 1 study, sponsored by University of Nebraska.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT02833701: Clinical Trial Phase 1 study, sponsored by University of Nebraska.
NCT02833701 is a Phase 1 study that was terminated before completion, run by University of Nebraska. The registered enrollment target is 9 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02833701, a Phase 1 study, was terminated before completion, sponsored by University of Nebraska.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of ascorbic acid when given together with bevacizumab in treating patients with high grade glioma that has come back (recurrent). Monoclonal antibodies, such as bevacizumab may interfere with the ability of tumor cells to grow and spread. Ascorbic acid contains ingredients that may prevent or slow the growth of high grade glioma. Giving bevacizumab and ascorbic acid together may work better in treating patients with high grade glioma.
Primary Outcome
Categorized by toxicity grades
Interventions
- OTHER Quality-of-Life Assessment
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL Bevacizumab
- DIETARY_SUPPLEMENT Ascorbic Acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2016-03 |
| Est. Completion | 2019-03 |
| Phase | Phase 1 |
Why NCT02833701 stopped before completion
NCT02833701 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 4 interventions - of which Quality-of-Life Assessment is the first listed.
NCT02833701 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02833701 about?
NCT02833701 is a clinical study titled "Bevacizumab and Ascorbic Acid in Patients Treating With Recurrent High Grade Glioma". This phase I trial studies the side effects and best dose of ascorbic acid when given together with bevacizumab in treating patients with high grade glioma that has come back (recurrent). Monoclonal antibodies, such as bevacizumab may interfere with the ability of tumor cells to grow and spread. Asc...
What is the current status of trial NCT02833701?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2016-03. Estimated completion is 2019-03.
What interventions are being tested in trial NCT02833701?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Laboratory Biomarker Analysis (OTHER), Bevacizumab (BIOLOGICAL), Ascorbic Acid (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02833701?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02833701's enrollment target sits among peer trials
9 1955th of 2000 higher than 42 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia